Compare GRFS & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRFS | INSP |
|---|---|---|
| Founded | 1940 | 2007 |
| Country | Spain | United States |
| Employees | 25247 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 1.6B |
| IPO Year | N/A | 2018 |
| Metric | GRFS | INSP |
|---|---|---|
| Price | $7.66 | $40.17 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 16 |
| Target Price | $10.15 | ★ $94.00 |
| AVG Volume (30 Days) | 590.7K | ★ 1.0M |
| Earning Date | 07-28-2022 | 05-04-2026 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | N/A | ★ 179.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $82,050,000.00 |
| Revenue This Year | $4.49 | $8.02 |
| Revenue Next Year | $6.42 | $8.11 |
| P/E Ratio | $18.67 | ★ N/A |
| Revenue Growth | N/A | ★ 62.18 |
| 52 Week Low | $7.39 | $41.52 |
| 52 Week High | $11.14 | $152.36 |
| Indicator | GRFS | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 39.40 | 27.58 |
| Support Level | $7.39 | N/A |
| Resistance Level | $9.78 | $59.40 |
| Average True Range (ATR) | 0.22 | 2.74 |
| MACD | -0.06 | -1.04 |
| Stochastic Oscillator | 16.06 | 3.06 |
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.